Saturday, October 20, 2018

The quest to determine which prostate cancers need treatment

Image courtesy University of York
CANCER DIGEST – Oct. 20, 2018 – Researchers  from the University of York in the UK and the University of British Columbia, Canada say they can now determine with 92 percent accuracy which prostate cancers are life-threatening and which can be managed.

Prostate cancers are generally categorized as slow-growing or aggressive. Slow-growing cancers that remain within the prostate can be monitored, sometimes for years before treatment is needed, while aggressive cancers need to be treated quickly.

Saturday, October 13, 2018

Stomach ulcer bacteria might also be linked to colorectal cancer

Electron micrograph of H. pylori - copy-
right free image from Wikipedia 
CANCER DIGEST – Oct. 13, 2018 – Could a round of antibiotics prevent colorectal cancer? That’s the intriguing question coming out a new Duke University study that links the bacterium H. pylori to an increased risk of of colorectal cancers. 


The study analyzed 4,000 colorectal cancer cases and found a significant correlation between colorectal cancer and those infected with a particularly virulent strain of H. pylori that is especially common among African Americans and Asians.

Saturday, September 22, 2018

Obesity and vitamin D deficiency may boost breast cancer risk

CANCER DIGEST – Sept. 22, 2018 – A new study shows that vitamin D may reduce cancer risk as well as breast cancer mortality, especially in slender or average-weight women.

The study involving 600 Brazilian women showed that obese post menopausal women diagnosed with breast cancer had an increased risk of vitamin D deficiency compared to women of the same age group who did not have breast cancer. The study appears in the September issue of the journal Menopause.

Saturday, September 15, 2018

Anti-inflammatory diet linked to lower risk of cancer and cardiovascular diseases

CANCER DIGEST – Sept. 15, 2018 – Adhering to an anti-inflammatory diet was associated with lower risk of dying from cancer as well as cardiovascular causes, according to a new study in the Sept. 2018 Journal of Internal Medicine.

The results showed that the more closely the participants followed an anti-inflammatory diet the lower their risk of dying form cancer or cardiovascular causes.

“Our dose-response analysis showed that even partial adherence to the anti-inflammatory diet may provide a health benefit,” said lead author Dr. Joanna Kaluza, an associate professor at the Warsaw University of Life Sciences, in Poland.

Saturday, September 8, 2018

Test or not to test is the question facing men with regard to prostate cancer

Illustration courtesy of SonaCare
CANCER DIGEST – Sept. 8, 2018 – An international panel of clinical experts recommends against routine testing for prostate cancer. That recommendation followed an extensive review of the available research that they say shows little evidence that such screening reduces prostate cancer deaths. Their findings are published online ahead of the Sept. 5, 2018 British Medical Journal (BMJ).

Saturday, August 25, 2018

Treatment for severe heartburn prevents cancer

CANCER DIGEST – Aug. 25, 2018 – Medication or surgery to treat severe heartburn prevents cancer of the esophagus, say Swedish researchers at the Karolinska Institute.

In the study, researchers analyzed data from more than 940,000 patients treated for acid reflux between 1964 and 2014 in five Scandinavian countries. Of the those with reflux in the study, about 895,000 received medical treatment. A total of 2,370 of those treated (0.3 per cent) developed cancer of the esophagus during the follow-up period. The study findings are published online Aug. 23, 2018 by the journal JAMA Oncology.

Saturday, August 18, 2018

Fast-tracked breast cancer drug boosts progression-free survival

Image courtesy of the Talazoparib 
Beyond BRCA (TBB) Trial
CANCER DIGEST – Aug. 18, 2018 – Just a month after the FDA granted it a priority review, the breast cancer drug Talazoparib has shown that it significantly extends progression free survival and improved quality of life compared to similar patients treated with current standard therapies.

Talazoparib is an investigational anticancer drug called a PARP (poly ADP ribose polymerase) inhibitor, which is being evaluated in breast cancer patients with BRCA gene mutations, as well as other cancer types. The international study was led by Jennifer Litton, MD at M.D. Anderson Cancer Center and published in the Aug. 15, 2018 New England Journal of Medicine.

Saturday, August 11, 2018

CLL patients need to be monitored for developing melanoma

CANCER DIGEST – Aug. 11, 2018 – People with a form of leukemia called chronic lymphocytic leukemia (CLL) have a substantially higher risk of melanoma, the deadly form of skin cancer, researcher report.

Although the higher risk of melanoma for CLL patients had been known, a full analysis of the relationship has never been done before researchers led by Clive Zent, MD of the Wilmot cancer Institute reported findings in the August 2018 journal Leukemia Research.

Saturday, August 4, 2018

Healthy diet cuts cancer risk


CANCER DIGEST – Aug. 4, 2018 – A diet that encourages both healthy eating and physical activity and discourages alcohol consumption was associated with a reduced overall cancer risk, as well as lower breast, prostate, and colorectal cancer risks.

The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) estimated that in developed countries, around 35 percent of breast cancers and 45 percent of colorectal cancers could be avoided by better adherence to nutritional recommendations.

Many organizations have issued dietary recommendations, but this study evaluated three previously validated nutritional recommendations: The World Cancer Research Fund/American Institute for Cancer Research

Saturday, July 21, 2018

Diabetes increases risk of cancer and even more so for women

CANCER DIGEST – July 21, 2018 – A new population study involving 20 million people has found that having diabetes, either type 1 or 2, increases the risk of cancer compared to people without diabetes.

The researchers, led by Dr. Toshiaki Ohkuma, at the George Institute for Global Health at Oxford University analyzed data from 47 studies from the USA, Japan,

Saturday, July 14, 2018

Study Finds Robotic Surgery is as Effective as Open Surgery for Bladder Cancer


Photo courtesy Loyola University Medical Center
CANCER DIGEST – July 14, 2018 – Robotic assisted surgery has been shown to be as effective as conventional open surgery for the treatment of bladder cancer according to a new multi-center study published in the June 23, 2018 The Lancet.

Saturday, July 7, 2018

High-intensity ultrasound as effective as surgery but with fewer side effects for prostate cancer

Image courtesy of SonaCare
CANCER DIGEST – July 7, 2018 – Using high-energy ultrasound to eradicate prostate cancer may be as effective as surgery or radiation, but with fewer side effects, researchers say.

In a new study of the treatment called high-intensity focused ultrasound (HIFU), researchers at the Imperial College London and University College London and four other hospitals in the UK tracked 625 men with early stage prostate cancer treated with HIFU for a median of nearly

Saturday, June 30, 2018

Poliovirus significantly boosts survival in deadly brain cancer

Image courtesy Duke Health
CANCER DIGEST – June 30, 2018 – Using a genetically modified poliovirus researchers at Duke Cancer Institute have significantly improved long-term survival for patients with recurrent glioblastoma, a deadly form of brain cancer.

The early stage clinical trial results of the poliovirus therapy were presented June 26 at the 22nd International Conference on Brain Tumor Research and Therapy in Norway and simultaneously published in June 26, 2018 The New England Journal of Medicine.

Saturday, June 23, 2018

Cyanide drug cuts hearing loss in half in children treated for liver cancer

Photo courtesy of CDC Early Hearing Detection and
Intervention program
CANCER DIGEST – June 21, 2018 – A drug used as an antidote to cyanide poisoning reduces hearing loss by nearly 50 percent in children treated with chemotherapy for liver cancer, researchers say.

The drug is sodium thiosulphate (STS) and has been used for decades primarily as an antidote to cyanide poisoning, and is also used as a chemical to reduce excess chlorine levels in swimming pools. In the study published in the New England Journal of Medicine, British researchers led by Dr. Penelope Brock for Cancer Research UK treated children with a rare type of childhood liver cancer called hepatoblastoma.

Saturday, June 16, 2018

Higher levels of vitamin D linked to lower colorectal cancer risk in women

CANCER DIGEST – June 15, 2018 – People with higher levels of vitamin D in their blood appear to have protection against colorectal cancer, according to a new study in the Journal of the National Cancer Institute.

Vitamin D plays a key role in maintaining bone health, but research has produced clues that it may also lower the risk of colorectal cancer due to effects on cell growth and regulation, however the studies aimed to evaluate a protective effect have been inconsistent.

Saturday, June 9, 2018

Immunotherapy approach wiped out advanced breast cancer patient's tumors

CT scans 14 months after treatment (right) 
show all tumors have disappeared. 
Image provided by National Cancer Institute
CANCER DIGEST – June 9, 2018 – Researchers at the National Cancer Institute used certain cells taken from a breast cancer patient’s immune cells to wipe out all tumors in a case of advanced disease that had spread to other parts of the body.

The patient with metastatic disease had undergone several other treatments, including chemotherapy and hormonal treatments that had not stopped her cancer from progressing.

Monday, May 28, 2018

FDA-approved drug for blood cancer holds promise for aggressive breast cancer

CANCER DIGEST – May 28, 2018 – An already FDA- approved drug for the treatment of certain blood cancers, could significantly inhibit the growth of triple-negative breast cancers, and also treat tumors resistant to chemotherapy.

The drug called decitabine is used to treat myelodysplastic syndrome, a type of cancer that produces abnormal blood forming cells in bone marrow.

Saturday, May 19, 2018

New regimen could cut cost of breast cancer treatment in half

Herceptin has been shown to prolong survival in about 12
percent of women whose breast cancer is positive for the
gene HER2 and has not spread to other parts of the body.
Image courtesy Roche Pharmaceuticals
CANCER DIGEST – May 19, 2018 – A new study shows that treatment with half as much of an expensive breast cancer drug is just as effective as the current treatment regimen.

The study of 4,088 women with HER2-positive, early stage breast cancer showed that 89.4% of women treated for just 6 months with the expensive drug trastuzumab (Herceptin) remained disease free compared to 89.9% of the women treated for 12 months with the drug. The difference is not trivial with a drug that costs about $54,000 per month.

Saturday, May 12, 2018

Could fasting help people treated for gastrointestinal cancer?

Intestinal stem cells from mice that fasted for 24 hours,
at right, produced much more substantial intestinal
organoids than stem cells from mice that did not fast,
at left. Photo courtesy MIT taken by 
Maria Mihaylova
and Chia-Wei Cheng
CANCER DIGEST – May 12, 2018 – In a study in mice, researchers at MIT in Boston have found that fasting caused stem cells in the animals become more regenerative. The researchers also found that they could boost regeneration with a molecule that activates the same metabolic switch.

The study published in the May 3, 2018 issue of the journal Cell Stem Cell, showed that fasting causes cells in the intestine to switch from their usual metabolism, which burns carbohydrates such as sugars, to metabolizing fatty acids. This switch occurs through activation of genetic switches called transcription factors.

Saturday, May 5, 2018

Osteoprosis drug may be effective for aggressive breast cancer

CANCER DIGEST – May 5, 2018 – A common drug used to treat osteoporosis may be key to halting the most aggressive form of breast cancer, researchers say.

The drug zoledronic acid (Zometa®) is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer. It is used in combination with chemotherapy for cancers of the breast and lung that have spread to bones.

Sunday, April 22, 2018

Four dollar drug might be effective against most aggressive prostate cancers

The cell's mitochondria produce the energy that fuels the
cell. Metformin may be used to shut down mitochondria
in aggressive prostate cancer cells 
CANCER DIGEST – April 22, 2018 – New research shows how a common drug for diabetes may halt aggressive prostate cancer.

The drug metformin has long been linked with anti-cancer properties as numerous studies have shown lower rates of certain cancers among diabetic patients who take the drug, but just how the drug might work against cancer was unknown.

Saturday, April 14, 2018

Double-drug strategy blocks escape route for most lung cancers

The tumors in the top three rows above were treated with
 current drugs, the bottom row tumors were treated with the
new combination. Image courtesy of UT Southwestern
CANCER DIGEST – April 14, 2018 – A combination of two, already FDA-approved drugs, appear to be effective in treating non-small lung cancer, at least in mice models that had human-derived tumors, researchers say. Because the two drugs are already approved, the researchers hope to have a clinical trial in humans approved within a year.

The two drugs include a class of drugs called EGFR inhibitors such as Erbitux®, Tarceva® and Iressa®, and the class of TNF inhibitors such as Humira®, Enbrel® and Remicade®.

Sunday, April 8, 2018

New combination shows promise in advanced lung cancer

CANCER DIGEST – April 8, 2018 – A new combination therapy of using an immunotherapy drug, with a new and powerful immune stimulation drug, shows promise in patients whose advanced lung cancer has become resistant to other therapies, preliminary results of a clinical trial shows.

The study is the first time the immune stimulant has been combined with one of the new class of drugs, called checkpoint drugs such as nivolumab (OPDIVO®) and pembrolizumab (Keytruda) according to study leaders Drs. John Wrangle, and Mark Rubinstein, PhD., of the Hollings Cancer Center at the Medical University of South Carolina.

Saturday, March 17, 2018

Medicare will cover genetic tests for cancer patients

CANCER DIGEST – Mar. 17, 2018 – The Centers for Medicare & Medicaid Services (CMS) announced on Mar. 16 that Medicare will cover genetic testing needed to match cancer patients with targeted immunotherapies. Specifically Medicare will cover Next Generation Sequencing (NGS) for patients with advanced cancer that has spread or has relapsed or fails to respond to other therapies.

Saturday, March 10, 2018

UK’s National Health Service to trial mpMRI for prostate cancer

Patient being positioned for an MRI – image used under
Creative Commons share alike license from Wikipedia
CANCER DIGEST – March 10, 2018 –In an effort to improve and speed up prostate cancer diagnosis, Britain’s National Health Service has launched a trial of a "one-stop" service in three west London hospitals. The goal is to complete all the tests needed to tell a man whether or not he has prostate cancer in one day.

Saturday, February 24, 2018

Trojan Horse targets metastatic cancer

Image credit: Pellecchia Lab, UC Riverside
CANCER DIGEST – Feb. 24, 2018 – Researchers have developed a Trojan Horse that delivers anti-cancer drug to a metastatic cancer cell. If proven successful, it could be used to reduce or halt metastases, which is the leading cause of death in cancer.

Once cancer metastasizes, or spreads to other parts of the body, there is no current therapy that can target those traveling cancer cells, and chemotherapy is indiscriminate, destroying healthy as well as cancerous cells.

Saturday, February 17, 2018

Accuracy of tests for predicting breast cancer recurrence vary significantly

Image courtesy Queen Mary
University of London
CANCER DIGEST – Feb. 17, 2018 – Tests used to predict breast cancer recurrence vary significantly in accuracy according to the first side-by-side comparison of the four most common tests.

In a study published in the Feb. 15, 2018 journal JAMA Oncology researchers led by Ivana Sestak, PhD of the Centre for Cancer Prevention at Queen Mary University of London, compared the predictive performance of the four most widely used biomarker analysis tests: Oncotype DX, PAM50, Breast Cancer Index (BCI) and the EndoPredict (EPclin), which all work by looking at the levels of multiple genes related to breast cancer.

Saturday, February 10, 2018

Imaging-first strategy effective for prostate cancer


CANCER DIGEST – Feb. 9, 2018 – An advanced imaging technique is a cost-effective first test for the diagnosis of prostate cancer when followed by a combination imaging-guided biopsy say researchers.

The PROMIS study published in the January 2018 European Urology was designed to compare cost and effectiveness of three diagnostic strategies: transrectal ultrasound-guided biopsy (TRUSB), template prostate mapping biopsy (TPMB), and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer.

Friday, January 19, 2018

Another blood test for cancer shows promise


CANCER DIGEST – Jan. 19, 2018 – A team of researchers have developed another blood test for cancer, which if confirmed in clinical trials, could identify eight cancer types from a single blood draw.

The team at Johns Hopkins University of School of Medicine published its findings in the Jan. 18, 2018 journal Science. The test, called CancerSEEK simultaneously evaluates the levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood. Five of the cancers currently have no screening test.

Saturday, January 13, 2018

New test predicts age of onset of aggressive prostate cancer

CANCER DIGEST – Jan. 13, 2018 – A new test based on genomic research combined with population research is able to predict the age of onset of aggressive prostate cancer, researchers say.

The tool is based on searches of individual genomes, the entire set of genes that make up an individual, for small variations, called single-nucleotide polymorphisms or SNPs that occur more frequently in people with a particular disease compared to people without the disease.